MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
– Primary endpoint achieved statistically significant improvement in MDD symptoms – – Confirmation of activity of lysergide in brain health disorders with direct relevance to... | April 14, 2023
Robert Barrow Matthias Liechti Felix Mueller Medicine Mindmed Inc University Hospital Basel Company Or Mindmed
Source: marketscreener.com